NASDAQ · Financial Statements
Grace Therapeutics, Inc. (GRCE) Financial Statements
$2.08
NASDAQ: GRCE
Market Cap $33.85M
Overview Financials Dividend
Grace Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $8.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2022 2023 2024 2025 2026
Revenue $0 $0 $0 $0 $0 Operating Profit $-19.0M $-71.0M $-17.0M $-24.0M $-11.0M Net Profit $-12.0M $-57.0M $-17.0M $-14.0M $-8.0M EPS $-2.02 $-7.72 $-1.83 $-1.13 $-0.47 Op Margin — — — — —
Balance Sheet (USD)
Metric 2022 2023 2024 2025 2026
Total Assets $129.0M $79.0M $73.0M $72.0M $67.0M Total Liabilities $20.0M $11.0M $12.0M $5.0M $3.0M Cash $30.0M $28.0M $23.0M $22.0M $17.0M Borrowings $0 $0 $0 $0 $0
Cash Flow (USD)
Metric 2022 2023 2024 2025 2026
Operating Cash Flow $-17.0M $-16.0M $-12.0M $-15.0M $-9.0M Investing Cash Flow $-4.0M $13.0M $0 $0 $0 Financing Cash Flow $0 $0 $0 $-1.0M $0 Net Cash Flow $-21.0M $-2.0M $-5.0M $-1.0M $-5.0M Free Cash Flow $-17.0M $-16.0M $-12.0M $-15.0M $-9.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.01 EV / EBITDA -0.77 FCF Yield -30.73% Quick Ratio 11.47 Interest Coverage — Return 1Y -23.35% Return 3Y -2.20% Return 5Y -89.81%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .